| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911325 | Lung Cancer | 2012 | 5 Pages |
Abstract
This trial evaluating the addition of bevacizumab to cisplatin and pemetrexed in patients with previously untreated, advanced MM failed to meet the primary endpoint of a 33% improvement in the progression-free survival rate at 6Â months compared with historical controls treated with cisplatin and pemetrexed alone.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jonathan E. Dowell, Frank R. Dunphy, Robert N. Taub, David E. Gerber, Likheng Ngov, Jingsheng Yan, Yang Xie, Hedy Lee Kindler,